(Q38253823)

1 September 2017

1 reference

title

Ipilimumab in the treatment of advanced melanoma - a clinical update (English)

1 reference

1 September 2017

0 references

Dae Won Kim

1

1 reference

1 September 2017

Van Anh Trinh

series ordinal

2

1 reference

1 September 2017

Wen-Jen Hwu

series ordinal

3

1 reference

1 September 2017

language of work or name

English

0 references

publication date

24 September 2014

1 reference

Expert Opinion on Biological Therapy

1 September 2017

published in

1 reference

1 September 2017

volume

14

1 reference

1 September 2017

issue

11

1 reference

1 September 2017

page(s)

1709-1718

1 reference

Ipilimumab in the treatment of melanoma

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Determinants of outcome in melanoma patients with cerebral metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Guidelines for the safe administration of high-dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Treg and CTLA-4: two intertwining pathways to immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.963053

10.1517/14712598.2014.963053

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference